Endo International plc

    [td_text_with_title custom_title=”Endo International plc”]Endo International plc is a global specialty pharmaceutical company focused on improving patients’ lives while creating value. Endo develops, manufactures, markets and distributes quality branded pharmaceutical and generic pharmaceutical products as well as over-the-counter medications through its operating companies – Endo Pharmaceuticals, Qualitest, AMS, Paladin Labs and SOMAR. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights, and assets from The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices and International Pharmaceuticals.

    Endo’s strategy is to maximize value for our key stakeholders by employing a lean operating model with focused and disciplined execution that allows us to pursue growth opportunities both organically and through selective acquisitions. Additionally, we are leveraging a research and development model that focuses on lower risk, near-term projects. Our goal is to consistently create value for our shareholders while serving our patients and customers.

    Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 5,000 people worldwide*.

    *As of 12/31/2014[/td_text_with_title]


    Posts not found

    [td_text_with_title custom_title=”Latest post”]

    Boston Scientific Acquires American Medical Systems’ Urology Portfolio For Up To $1.65 Billion

    Boston Scientific Announces Definitive Agreement To Acquire American Medical Systems’ Urology Portfolio For Up To $1.65 Billion Combined Business to Advance Patient Care with Leading Solutions Across Major Urology Categories MARLBOROUGH, Mass., March 2, 2015 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Endo International […]

    [/td_text_with_title][td_text_with_title custom_title=”From Wikipedia”]

    Endo International plc is a generics and specialty branded pharmaceutical company. It was created as a result of a management buyout from DuPont Merck in 1997 led by Carol Ammon.[1]

    History and Acquisitions

    In 2009, Endo bought Indevus Pharmaceuticals to diversify into endocrinology and oncology.[2] The company entered the male hypogonadism market later in 2010 with Fortesta 2% gel.[2]

    In November 2013, Endo agreed to purchase Paladin Labs Inc for about $1.6 billion to gain access to the Canadian market as well as expand into emerging markets.[3][4]

    In October 2014, Endo said it would buy Auxilium Pharmaceuticals for $2.6 billion,[5] along with its testosterone replacement therapy products.[6]

    In 2015, Endo acquired the specialty generics and sterile injectables company Par Pharmaceutical for $8.05 billion.[7]

    In 2018, Endo settled over 1,200 lawsuits related to its testosterone replacement therapy, Testim, and its undisclosed side effects.[6]

    Acquisition attempts

    In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million.[8] However, Teva prevailed in this acquisition with a substantially higher bid.[9]


    Endo is one of the companies named in lawsuits by the states of Ohio,[10] Missouri and Mississippi[11] as responsible for the US opioid epidemic. Its 10-K statement indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids.[12]

    On June 8, 2017, the U.S. Food and Drug Administration (FDA) released a press statement in which it announced that it had requested Endo to withdraw its opioid drug, oxymorphone hydrochloride (Opana ER), from the market. It was the first time that the FDA had "taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse."[13]

    See also


    1. ^ Schneiderman, R.M. (9 April 2007). "Ammon Exits Endo". Forbes. 
    2. ^ a b Associated Press (2009-01-06). "Endo to buy Indevus". The Boston Globe. Retrieved 2009-06-28. 
    3. ^ Rubin, Ben Fox (5 November 2013). "Endo Health to Buy Paladin Labs for $1.6 Billion". Wall Street Journal. 
    4. ^ "Endo Health to Buy Specialty Drug Maker for $1.6 Billion". New York Times Dealbook. November 5, 2013. 
    5. ^ "Endo Scores with $2.6B Offer for Auxilium, Which Ends QLT Deal | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN". GEN. October 9, 2014. 
    6. ^ a b George, John (12 June 2018). "Endo executes master settlement agreement to resolve testosterone lawsuits". Philadelphia Business Journal. Retrieved 4 July 2018. 
    7. ^ Bray, Chad (18 May 2015). "Endo International to Pay $8.05 Billion for Par Pharmaceutical". The New York Times. 
    8. ^ "Endo to Purchase NuPahte for $150M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper)|format= requires |url= (help). 34 (2). January 15, 2014. p. 10. 
    9. ^ "Teva Outbids Endo, Acquires NuPathe for $144M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper). 34 (4). February 15, 2014. p. 10. 
    10. ^ Dwyer, Colin (31 May 2017). "Ohio Sues 5 Major Drug Companies For 'Fueling Opioid Epidemic'". NPR Online. 
    11. ^ Raymond, Nate (21 Jun 2017). "Missouri sues opioid manufacturers, joining two other U.S. states". Reuters. 
    12. ^ "Eondo Pharmaceuticals, FORM 10-K". 31 Dec 2016. 
    13. ^ "FDA requests removal of Opana ER for risks related to abuse" (Press release). FDA. June 8, 2017. 

    External links

    source: https://en.wikipedia.org/wiki/Endo_International[/td_text_with_title]